Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
50.11 (1y: +60%)
Market Cap 47.14 B P/E(ttm) 22.30
Enterprise Value 51.06 B P/B 2.60
WAG- NYSE (USA)
Walgreen Company
  • Currently 4/5
Business Predictability Rank: 4-Star (On Watch)
Back Testing Results:
Average gain of all 4-Star stocks: 9.8% per year.
% of Stocks that are in still loss if held for 10yrs: 8%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$50.11
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt 0.241
WAG's Cash to Debt is ranked lower than
70% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.55 vs. WAG: 0.241 )
WAG' s 10-Year Cash to Debt Range
Min: 0.04   Max: No Debt
Current: 0.24
Equity to Asset 0.442
WAG's Equity to Asset is ranked higher than
65% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.34 vs. WAG: 0.442 )
WAG' s 10-Year Equity to Asset Range
Min: 0.42   Max: 0.63
Current: 0.44
0.42
0.63
Interest Coverage 39.4
WAG's Interest Coverage is ranked lower than
55% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 41.95 vs. WAG: 39.4 )
WAG' s 10-Year Interest Coverage Range
Min: 39   Max: No Debt
Current: 39.4
F-Score: 5
Z-Score: 4.9
M-Score: -2.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry		 vs
history
Operating margin (%) 4.80
WAG's Operating margin (%) is ranked higher than
71% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.80 vs. WAG: 4.80 )
WAG' s 10-Year Operating margin (%) Range
Min: 4.8   Max: 6
Current: 4.8
4.8
6
Net-margin (%) 3
WAG's Net-margin (%) is ranked higher than
67% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.50 vs. WAG: 3 )
WAG' s 10-Year Net-margin (%) Range
Min: 3   Max: 3.8
Current: 3
3
3.8
ROE (%) 11.7
WAG's ROE (%) is ranked higher than
53% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.80 vs. WAG: 11.7 )
WAG' s 10-Year ROE (%) Range
Min: 11.7   Max: 18.4
Current: 11.7
11.7
18.4
ROA (%) 6.4
WAG's ROA (%) is ranked higher than
59% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.20 vs. WAG: 6.4 )
WAG' s 10-Year ROA (%) Range
Min: 6.4   Max: 10.9
Current: 6.4
6.4
10.9
ROC (Joel Greenblatt) (%) 24.60
WAG's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 16.00 vs. WAG: 24.60 )
WAG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 22.7   Max: 30.7
Current: 24.6
22.7
30.7
Revenue Growth (%) 6.2
WAG's Revenue Growth (%) is ranked higher than
90% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.20 vs. WAG: 6.2 )
WAG' s 10-Year Revenue Growth (%) Range
Min: 6.2   Max: 12.1
Current: 6.2
6.2
12.1
EBITDA Growth (%) 5.4
WAG's EBITDA Growth (%) is ranked higher than
85% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.25 vs. WAG: 5.4 )
WAG' s 10-Year EBITDA Growth (%) Range
Min: 4.5   Max: 11.5
Current: 5.4
4.5
11.5
EPS Growth (%) 4.6
WAG's EPS Growth (%) is ranked higher than
81% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.70 vs. WAG: 4.6 )
WAG' s 10-Year EPS Growth (%) Range
Min: 1.1   Max: 12.4
Current: 4.6
1.1
12.4
ยป WAG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

WAG Guru Trades in Q2 2012

Manning & Napier Advisors, Inc 43,709 sh (New)
David Dreman 41,325 sh (New)
Ray Dalio 801,246 sh (+652.02%)
Paul Tudor Jones 59,400 sh (+224.59%)
John Rogers 261,085 sh (+64.32%)
Chuck Royce 88,740 sh (+47.51%)
Tom Gayner 868,860 sh (+26.87%)
John Buckingham 179,303 sh (+18.5%)
Joel Greenblatt 25,227 sh (+12.53%)
Bill Frels 16,538 sh (+8.08%)
First Pacific Advisors 2,272,300 sh (+5.99%)
Steven Romick 2,175,000 sh (+4.9%)
Vanguard Health Care Fund 10,544,700 sh (+1.93%)
Mario Gabelli 227,088 sh (+1.75%)
Ken Fisher 7,206 sh (+1.01%)
John Hussman 3,001,500 sh (unchged)
Louis Moore Bacon 75,000 sh (unchged)
Meridian Funds 15,400 sh (unchged)
Donald Yacktman 52,100 sh (unchged)
Paul Tudor Jones 250,000 sh (unchged)
Bruce Kovner Sold Out
Charles Brandes Sold Out
Louis Moore Bacon Sold Out
George Soros Sold Out
Chris Davis 3,671,938 sh (-0.68%)
James Barrow 9,265,699 sh (-3.19%)
Pioneer Investments 3,238,818 sh (-6.01%)
Tom Russo 1,500 sh (-26.83%)
Dodge & Cox 26,269 sh (-50.73%)
Charles de Vaulx 411,294 sh (-78.41%)
Jeremy Grantham 642,629 sh (-81.21%)
Steven Cohen 9,621 sh (-92.22%)
» More
Q3 2012

WAG Guru Trades in Q3 2012

Leon Cooperman 1,884,200 sh (New)
George Soros 3,630,300 sh (New)
Steven Cohen 1,230,596 sh (+12690.7%)
Tom Gayner 2,150,060 sh (+147.46%)
Chuck Royce 105,600 sh (+19%)
James Barrow 9,912,454 sh (+6.98%)
Vanguard Health Care Fund 10,844,700 sh (+2.85%)
Manning & Napier Advisors, Inc 44,800 sh (+2.5%)
First Pacific Advisors 2,272,800 sh (+0.02%)
Meridian Funds 15,400 sh (unchged)
Steven Romick 2,175,000 sh (unchged)
Donald Yacktman Sold Out
Paul Tudor Jones Sold Out
Ken Fisher Sold Out
Charles de Vaulx Sold Out
Bill Frels 16,463 sh (-0.45%)
David Dreman 40,655 sh (-1.62%)
Pioneer Investments 3,140,168 sh (-3.05%)
John Buckingham 167,153 sh (-6.78%)
Mario Gabelli 194,368 sh (-14.41%)
John Rogers 210,650 sh (-19.32%)
Jeremy Grantham 459,891 sh (-28.44%)
John Hussman 2,001,500 sh (-33.32%)
Tom Russo 1,000 sh (-33.33%)
Dodge & Cox 13,869 sh (-47.2%)
Ray Dalio 245,946 sh (-69.3%)
Joel Greenblatt 6,794 sh (-73.07%)
Chris Davis 702,033 sh (-80.88%)
» More
Q4 2012

WAG Guru Trades in Q4 2012

Ken Fisher 6,659 sh (New)
Paul Tudor Jones 612,500 sh (New)
NWQ Managers 15,850 sh (New)
Chuck Royce 125,700 sh (+19.03%)
Bill Frels 17,163 sh (+4.25%)
Steven Cohen 1,245,617 sh (+1.22%)
Manning & Napier Advisors, Inc 45,252 sh (+1.01%)
First Pacific Advisors 2,277,100 sh (+0.19%)
Tom Gayner 2,152,460 sh (+0.11%)
Meridian Funds 15,400 sh (unchged)
Steven Romick 2,175,000 sh (unchged)
Vanguard Health Care Fund 10,844,700 sh (unchged)
Jeremy Grantham 233,407 sh (unchged)
David Dreman Sold Out
Leon Cooperman Sold Out
Joel Greenblatt Sold Out
Chris Davis Sold Out
James Barrow 9,862,536 sh (-0.5%)
John Buckingham 165,117 sh (-1.22%)
Mario Gabelli 188,800 sh (-2.86%)
Tom Russo 950 sh (-5%)
Pioneer Investments 2,772,390 sh (-11.71%)
John Hussman 1,753,000 sh (-12.42%)
John Rogers 164,450 sh (-21.93%)
Ray Dalio 157,446 sh (-35.98%)
Dodge & Cox 6,869 sh (-50.47%)
George Soros 175,000 sh (-95.18%)
» More
Q1 2013

WAG Guru Trades in Q1 2013

Larry Robbins 3,202,500 sh (New)
RS Investment Management 55,960 sh (New)
Jeremy Grantham 1,316,021 sh (+463.83%)
Manning & Napier Advisors, Inc 52,947 sh (+17%)
Vanguard Health Care Fund 11,670,400 sh (+7.61%)
Mario Gabelli 199,859 sh (+5.86%)
James Barrow 10,331,817 sh (+4.76%)
Bill Frels 17,363 sh (+1.17%)
Meridian Funds 15,400 sh (unchged)
John Rogers 164,450 sh (unchged)
Steven Romick 2,175,000 sh (unchged)
First Pacific Advisors 2,277,100 sh (unchged)
George Soros Sold Out
NWQ Managers Sold Out
Ray Dalio Sold Out
Tom Gayner 2,151,460 sh (-0.05%)
John Buckingham 163,618 sh (-0.91%)
Pioneer Investments 2,618,953 sh (-5.53%)
Dodge & Cox 6,469 sh (-5.82%)
Tom Russo 780 sh (-17.89%)
Ken Fisher 5,234 sh (-21.4%)
Chuck Royce 92,500 sh (-26.41%)
Paul Tudor Jones 352,500 sh (-42.45%)
John Hussman 538,000 sh (-69.31%)
Steven Cohen 319,222 sh (-74.37%)
» More
» Details

Insider Trades

Latest Guru Trades with WAG

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-03-31 Reduce -69.31%1.18%$37.01 - $47.68 $ 50.1122%538000
Vanguard Health Care Fund 2013-03-31 Add 7.61%0.16%$37.01 - $47.68 $ 50.1122%11670400
George Soros 2013-03-31 Sold Out 0.08%$37.01 - $47.68 $ 50.1122%0
Ray Dalio 2013-03-31 Sold Out 0.06%$37.01 - $47.68 $ 50.1122%0
George Soros 2012-12-31 Reduce -95.18%2%$32.16 - $37.55 $ 50.1143%175000
Leon Cooperman 2012-12-31 Sold Out 1.4%$32.16 - $37.55 $ 50.1143%0
Ray Dalio 2012-12-31 Reduce -35.98%0.04%$32.16 - $37.55 $ 50.1143%157446
David Dreman 2012-12-31 Sold Out 0.04%$32.16 - $37.55 $ 50.1143%0
Joel Greenblatt 2012-12-31 Sold Out 0.02%$32.16 - $37.55 $ 50.1143%0
Dodge & Cox 2012-12-31 Reduce -50.47%$32.16 - $37.55 $ 50.1143%6869
George Soros 2012-09-30 New Buy2.1%$29.41 - $36.59 $ 50.1146%3630300
Tom Gayner 2012-09-30 Add 147.46%1.97%$29.41 - $36.59 $ 50.1146%2150060
Leon Cooperman 2012-09-30 New Buy1.4%$29.41 - $36.59 $ 50.1146%1884200
John Hussman 2012-09-30 Reduce -33.32%0.57%$29.41 - $36.59 $ 50.1146%2001500
Ray Dalio 2012-09-30 Reduce -69.3%0.24%$29.41 - $36.59 $ 50.1146%245946
Joel Greenblatt 2012-09-30 Reduce -73.07%0.04%$29.41 - $36.59 $ 50.1146%6794
Donald Yacktman 2012-09-30 Sold Out 0.01%$29.41 - $36.59 $ 50.1146%0
Dodge & Cox 2012-09-30 Reduce -47.2%$29.41 - $36.59 $ 50.1146%13869
Ray Dalio 2012-06-30 Add 652.02%0.3%$28.69 - $35.8 $ 50.1155%801246
Tom Gayner 2012-06-30 Add 26.87%0.25%$28.69 - $35.8 $ 50.1155%868860
Charles Brandes 2012-06-30 Sold Out 0.07%$28.69 - $35.8 $ 50.1155%0
George Soros 2012-06-30 Sold Out 0.05%$28.69 - $35.8 $ 50.1155%0
David Dreman 2012-06-30 New Buy0.03%$28.69 - $35.8 $ 50.1155%41325
Dodge & Cox 2012-06-30 Reduce -50.73%$28.69 - $35.8 $ 50.1155%26269
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Walgreen Company

Guru Favorites Report Insider Transactions
April 22, 2013
Jim Simons,John Hussman - Guru Favorites Report Insider Transactions
This past week, several large corporations reported their corporate executives and directors making rather large transactions within their companies. All of the companies are at (or are nearing) a 10-year high in prices. Read more...
Going Back to Fundamentals (3): Debt to Equity
June 14, 2012
- Going Back To Fundamentals (3): Debt To Equity
In what might be considered by some as the simplest of criteria to evaluate, I have found that the debt to equity ratio actually can be very difficult or at best, time consuming. Why? Because once again, itโ€™s just a number, and it means nothing unless you compare it with peers in the same industry and delve deeper into some hidden meanings behind the number. Let me explain. Read more...
Going Back to Fundamentals (2): ROA
June 7, 2012
- Going Back To Fundamentals (2): ROA
In the first part of this series, I discussed the current ratio. These discussions, once again, are an attempt to induce the investor to really consider all the facets of each criterion or metric they are considering. Numbers are just thatโ€ฆ numbers. But without genuinely thinking about what those numbers actually mean to the investor, they become mechanical and eventually somewhat worthless. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 22.30
WAG's P/E(ttm) is ranked higher than
74% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 16.24 vs. WAG: 22.30 )
WAG' s 10-Year P/E(ttm) Range
Min: 10.2   Max: 56.74
Current: 22.3
10.2
56.74
P/B 2.60
WAG's P/B is ranked lower than
65% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.51 vs. WAG: 2.60 )
WAG' s 10-Year P/B Range
Min: 1.6   Max: 10.42
Current: 2.6
1.6
10.42
P/S 0.60
WAG's P/S is ranked lower than
62% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.30 vs. WAG: 0.60 )
WAG' s 10-Year P/S Range
Min: 0.36   Max: 2.07
Current: 0.6
0.36
2.07
PFCF 14.80
WAG's PFCF is ranked higher than
56% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.04 vs. WAG: 14.80 )
WAG' s 10-Year PFCF Range
Min: 9.86   Max: 399.5
Current: 14.8
9.86
399.5
EV-to-EBIT 14.9
WAG's EV-to-EBIT is ranked higher than
67% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.60 vs. WAG: 14.9 )
WAG' s 10-Year EV-to-EBIT Range
Min: 6.3   Max: 36
Current: 14.9
6.3
36
PEG 2.9
WAG's PEG is ranked higher than
89% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.20 vs. WAG: 2.9 )
WAG' s 10-Year PEG Range
Min: 0.65   Max: 3
Current: 2.9
0.65
3
Shiller P/E 20.3
WAG's Shiller P/E is ranked higher than
86% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.98 vs. WAG: 20.3 )
WAG' s 10-Year Shiller P/E Range
Min: 12.07   Max: 42.41
Current: 20.3
12.07
42.41

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 2.20
WAG's Dividend Yield is ranked higher than
81% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.82 vs. WAG: 2.20 )
WAG' s 10-Year Dividend Yield Range
Min: 0.31   Max: 3.11
Current: 2.2
0.31
3.11
Dividend Payout 0.4672
WAG's Dividend Payout is ranked higher than
64% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.52 vs. WAG: 0.4672 )
WAG' s 10-Year Dividend Payout Range
Min: 0.14   Max: 0.39
Current: 0.47
0.14
0.39
Dividend growth (3y) 18.9
WAG's Dividend growth (3y) is ranked higher than
98% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.70 vs. WAG: 18.9 )
WAG' s 10-Year Dividend growth (3y) Range
Min: 2.8   Max: 18.9
Current: 18.9
2.8
18.9
Yield on cost (5-Year) 6.61
WAG's Yield on cost (5-Year) is ranked higher than
98% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.91 vs. WAG: 6.61 )
WAG' s 10-Year Yield on cost (5-Year) Range
Min: 0.93   Max: 9.34
Current: 6.61
0.93
9.34
Share Buyback Rate 2.9
WAG's Share Buyback Rate is ranked higher than
94% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.30 vs. WAG: 2.9 )
WAG' s 10-Year Share Buyback Rate Range
Min: 2.9   Max: -0.4
Current: 2.9

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 9.2
WAG's Price/Net Current Asset Value is ranked higher than
84% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.75 vs. WAG: 9.2 )
WAG' s 10-Year Price/Net Current Asset Value Range
Min: 4.8   Max: 17.9
Current: 9.2
4.8
17.9
Price/Tangible Book 3.2
WAG's Price/Tangible Book is ranked higher than
81% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.10 vs. WAG: 3.2 )
WAG' s 10-Year Price/Tangible Book Range
Min: 2.1   Max: 7.9
Current: 3.2
2.1
7.9
Price/DCF (Projected) 1.2
WAG's Price/DCF (Projected) is ranked higher than
88% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.95 vs. WAG: 1.2 )
WAG' s 10-Year Price/DCF (Projected) Range
Min: 0.8   Max: 4.9
Current: 1.2
0.8
4.9
Price/Median PS Value 0.7
WAG's Price/Median PS Value is ranked higher than
69% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.95 vs. WAG: 0.7 )
WAG' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 1.7
Current: 0.7
0.4
1.7
Price/Peter Lynch Fair Value 3
WAG's Price/Peter Lynch Fair Value is ranked higher than
97% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.45 vs. WAG: 3 )
WAG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.1   Max: 2
Current: 3
1.1
2
Price/Graham Number 1.7
WAG's Price/Graham Number is ranked higher than
82% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.45 vs. WAG: 1.7 )
WAG' s 10-Year Price/Graham Number Range
Min: 1.1   Max: 3.9
Current: 1.7
1.1
3.9
Earnings Yield (Greenblatt) 6.70
WAG's Earnings Yield (Greenblatt) is ranked lower than
76% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.30 vs. WAG: 6.70 )
WAG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.8   Max: 15.9
Current: 6.7
2.8
15.9
Forward Rate of Return (Yacktman) 11.12
WAG's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 218 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.33 vs. WAG: 11.12 )
WAG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 10.6   Max: 18.6
Current: 11.12
10.6
18.6

Business Description

Walgreen Company was incorporated in the state of Illinois in 1909 as a successor to a business founded in 1901. Its corporate strategy is to provide convenient access to healthcare services and consumer goods in America through its 7,930 community based drugstores, as well as through its specialty pharmacy, home infusion, worksite health center and retail clinic businesses. The Company's drugstores are engaged in the retail sale of prescription and non-prescription drugs and general merchandise. General merchandise includes, among other things, household items, personal care, convenience foods, beauty care, photofinishing, candy, and seasonal items. Walgreens offers customers the choice to have prescriptions filled at the drugstore counter, as well as through the mail, by telephone and via the Internet. Inventories are purchased from numerous domestic and foreign suppliers. The business is seasonal in nature, with Christmas generating a higher proportion of front-end sales and earnings than other periods. Both prescription and non-prescription drug sales are affected by the timing and severity of the cold/flu season. The Company generally finances its inventory and expansion needs with internally generated funds. It sells to numerous customers including managed care organizations. Walgreens competes with different retailers, including chain and independent drugstores, mail order prescription providers, grocery stores, convenient stores, mass merchants and dollar stores. Its retail drugstore, pharmacy benefit and health services businesses are subject to numerous federal, state and local regulations.
Company Website
SEC Reports
Industry: Pharmaceutical Retailers
Compare:SHDMF, APNHF, GNC, JCOUF, PMC
Traded in other countries:WGN.Germany
ยป More Articles for WAG

Headlines

Articles On GuruFocus.com
Attractively valued dividend stocks to consider today May 14 2013 
20 Dividend Champions with Highest 10-Year Dividend Growth Rates Apr 24 2013 
Guru Favorites Report Insider Transactions Apr 22 2013 
Walgreen Co. (WAG) Dividend Stock Analysis Apr 05 2013 
10 Dividend Stocks with a 10% Yield in 10 Years Apr 03 2013 
Three Key Forces That Drive up Stock Prices Mar 25 2013 
Billionaire Leon Cooperman Big Shake Ups: Apple (AAPL), Sprint (S) And More Mar 24 2013 
Billionaire Paul Tudor Jones Shakeups: Apple (AAPL), eBay (EBAY) And More Mar 24 2013 
Amerisource Gains on Distribution Deal and DSW Falls on Weak Outlook Mar 19 2013 
How Much Money Will You Need Before Retiring? Mar 06 2013 


Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial